Description
Developer of biopharmaceutical therapies designed to treat pulmonary arterial hypertension (PAH) and related disorders. The company's pulmonary disease and kinase inhibitor technology treats crucial lung conditions, enabling patients suffering from lung diseases to access pulmonary drugs.
Contact Information
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Secondary Transaction - Private | 000 | Completed | Generating Revenue | |||
5. Grant | 01-Jan-2017 | 00000 | 000 | Completed | Generating Revenue | |
4. Grant | 01-Jan-2016 | 00.000 | 000 | Completed | Generating Revenue | |
3. Seed Round | 04-Mar-2015 | 000 | 000 | Completed | Generating Revenue | |
2. Debt - General | 01-Oct-2014 | Completed | Generating Revenue | |||
1. Grant | 27-Mar-2014 | $1.5M | Completed | Generating Revenue |
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Lung Therapeutics | Venture Capital-Backed | Austin, TX | 00 | 000.00 | 0000000000 0 | 000.00 |
000000000 (0000000 | Formerly VC-backed | Mechelen, Belgium | 0000 | 00.000 | 000000000 | 00.000 |
000000 000000 | Accelerator/Incubator Backed | Morristown, NJ | 0 | 00.000 | 000000000 | 00.000 |
00000000 000000000 | Venture Capital-Backed | Tucson, AZ | 0 | 000.00 | 00000000000 | 000.00 |
000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210038510-A1 | Formulations of kinase inhibitors and prostanoids | Pending | 08-Feb-2018 | 0000000000 | |
EP-3532063-A4 | Combination therapy for treating pulmonary hypertension | Pending | 27-Oct-2016 | 0000000000 | 0 |
US-10231966-B2 | Combination therapy for treating pulmonary hypertension | Active | 27-Oct-2016 | 0000000000 | 00 |
CA-3041679-A1 | Combination therapy for treating pulmonary hypertension | Pending | 27-Oct-2016 | 0000000000 | |
EP-3532063-A1 | Combination therapy for treating pulmonary hypertension | Pending | 27-Oct-2016 | A61K31/497 |
Name | Representing | Role | Since |
---|---|---|---|
Shreefal Mehta Ph.D | Self | Board Director | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
National Heart, Lung and Blood Institute | Government | 000 0000 | 000000 0 | ||
National Institutes of Health | Government | 000 0000 | 000000 0 |